cyclosporine has been researched along with Kawasaki Disease in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraoka, T; Kondo, Y; Tsuge, M | 1 |
| Honda, K; Ikeda, H; Motegi, S; Watanabe, T; Watanabe, Y | 1 |
| Furui, S; Matsubara, D; Minami, T; Oka, K; Sato, T; Seki, M; Suzuki, S; Yamagata, T; Yokomizo, A | 1 |
| Garrido-García, LM; Iglesias-Amaya, A; Moreno-Espinosa, S; Pardo-Díaz, E; Rivera-Rodriguez, L; Ruiz-Ontiveros, MA; Scheffler-Mendoza, S; Yamazaki-Nakashimada, MA | 1 |
| Furuichi, M; Hara, T; Kawano, Y; Kinoshita, K; Ohnishi, T; Sato, S; Suganuma, E; Takei, H; Uejima, Y | 1 |
| Báez, M; Borjas-Aguilar, KL; García-Pavón, S; Murata, C; Yamazaki-Nakashimada, MA | 1 |
| Gámez-González, LB; Hamada, H; Honda, T; Murata, C; Yamazaki-Nakashimada, MA; Yasukawa, K | 1 |
| Hoshina, T; Ito, T; Kusuhara, K; Taku, K | 1 |
| McCrindle, BW; Rowley, AH | 1 |
| Aoyagi, R; Ariga, T; Ayusawa, M; Ebata, R; Fujii, Y; Fujiwara, T; Fuse, S; Hamada, H; Hanaoka, H; Hashimura, Y; Hata, A; Higaki, T; Hirai, K; Hirono, K; Ishiguchi, Y; Kurotobi, S; Masuda, H; Nakayashiro, M; Nomura, Y; Okajima, Y; Okuma, Y; Onouchi, Y; Otsuki, A; Ouchi, K; Sato, J; Sato, T; Soga, T; Suzuki, H; Takada, N; Takatsuki, S; Terai, M; Terauchi, M; Yamamoto, E; Yanai, M | 1 |
| Burns, JC | 1 |
| Kakimoto, N; Shibuta, S; Suenaga, T; Suzuki, H; Takeuchi, T | 1 |
| Aoyagi, R; Ebata, R; Hamada, H; Hanaoka, H; Hata, A; Nagashima, K; Onouchi, Y; Sato, Y; Suzuki, H; Terai, M; Terauchi, M | 1 |
| Akase, H; Azuma, Y; Hasegawa, S; Korenaga, Y; Ohga, S; Okada, S; Suzuki, Y; Wakabayashi-Takahara, M; Yamada, H | 1 |
| Aoyagi, N; Hamada, H; Hata, A; Honda, T; Iwahashi, S; Miyashita, R; Miyawaki, M; Oishi, K; Onouchi, Y; Sasago, K; Shibuta, S; Suenaga, T; Suzuki, H; Suzuki, Y; Takeuchi, T; Terai, M; Yamaga, H; Yoshikawa, N | 1 |
| Bujold, M; Burns, JC; Dodd, D; Erdem, G; Franco, A; Onouchi, Y; Pancoast, P; Shimizu, C; Tamamoto, A; Tremoulet, AH | 1 |
| Abe, J; Aoyagi, N; Hamada, H; Hata, A; Honda, T; Iwahashi, S; Miyashita, R; Miyawaki, M; Oishi, K; Onouchi, Y; Shibuta, S; Suenaga, T; Suzuki, H; Suzuki, Y; Takeuchi, T; Terai, M; Yamaga, H; Yoshikawa, N | 1 |
| Burgner, D; Kuijpers, TW; Kuipers, IM; Tacke, CE | 1 |
| Harada, W; Hirokawa, T; Suzuki, H; Toyabe, S; Uchiyama, M | 1 |
| Achterhuis, A; Becker, AE; Biezeveld, M; Hack, CE; Kuijpers, TW; Kuipers, I; Lam, J; van der Wal, AC | 1 |
| Freeman, AF; Shulman, ST | 1 |
| Chatila, T; Kim, J; Raman, V; Sharkey, A | 1 |
4 review(s) available for cyclosporine and Kawasaki Disease
| Article | Year |
|---|---|
Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal; Aspartate Aminotransferases; Child; Child, Preschool; Coronary Vessel Anomalies; Cyclosporine; Etoposide; Female; Fever; Humans; Infant; Macrophage Activation Syndrome; Male; Mucocutaneous Lymph Node Syndrome; Tumor Necrosis Factor-alpha | 2017 |
Management of acute and refractory Kawasaki disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Murine-Derived; Aspirin; Chemotherapy, Adjuvant; Coronary Aneurysm; Cyclosporine; Enzyme Inhibitors; Humans; Immunoglobulins, Intravenous; Methotrexate; Mucocutaneous Lymph Node Syndrome; Rituximab; Tumor Necrosis Factor-alpha | 2012 |
Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect.
Topics: Aneurysm; C-Reactive Protein; Coronary Disease; Cyclosporine; Cytokines; Drug Resistance; Fatal Outcome; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Mucocutaneous Lymph Node Syndrome; Myocardial Infarction; Salicylates; Serine Endopeptidases | 2003 |
Refractory Kawasaki disease.
Topics: Anti-Inflammatory Agents; Aspirin; Cyclosporine; Drug Therapy, Combination; Fever; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methylprednisolone; Mucocutaneous Lymph Node Syndrome; Recurrence | 2004 |
3 trial(s) available for cyclosporine and Kawasaki Disease
| Article | Year |
|---|---|
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised cont
Topics: Child; Child, Preschool; Coronary Vessel Anomalies; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Female; Health Status Indicators; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Incidence; Japan; Male; Mucocutaneous Lymph Node Syndrome; Treatment Outcome | 2019 |
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Topics: Aspirin; Calcineurin Inhibitors; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Infant; Japan; Male; Mucocutaneous Lymph Node Syndrome; Proportional Hazards Models; Research Design; Treatment Outcome | 2015 |
Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Topics: Child; Child, Preschool; Cyclosporine; Cytokines; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Infant; Male; Mucocutaneous Lymph Node Syndrome; Pilot Projects; Treatment Outcome | 2012 |
15 other study(ies) available for cyclosporine and Kawasaki Disease
| Article | Year |
|---|---|
Cyclosporine for the treatment of multisystem inflammatory syndrome in children with coronary artery aneurysms.
Topics: Child; Coronary Aneurysm; Coronary Vessels; COVID-19; Cyclosporine; Female; Humans; Immunoglobulins, Intravenous; Interleukin 1 Receptor Antagonist Protein; Mucocutaneous Lymph Node Syndrome; Systemic Inflammatory Response Syndrome | 2022 |
Kawasaki disease complicated by aspergillosis under cyclosporine and infliximab.
Topics: Aspergillosis; Cyclosporine; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infliximab; Mucocutaneous Lymph Node Syndrome | 2022 |
Continuous cyclosporine a infusion in patients with severe Kawasaki disease.
Topics: C-Reactive Protein; Coronary Artery Disease; Cyclosporine; Humans; Immunoglobulins, Intravenous; Infant; Mucocutaneous Lymph Node Syndrome; Treatment Outcome | 2022 |
Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
Topics: Adrenal Cortex Hormones; Adult; Child, Preschool; Cyclosporine; Dermatologic Agents; Female; Humans; Immunoglobulins, Intravenous; Infliximab; Macrophage Activation Syndrome; Male; Mucocutaneous Lymph Node Syndrome; Young Adult | 2021 |
A Case of Intravenous Immunoglobulin-Resistant Kawasaki Disease With Yersinia enterocolitica Enterocolitis Successfully Treated With Cefotaxime Following Infliximab and Cyclosporine.
Topics: Cefotaxime; Cyclosporine; Enterocolitis; Humans; Immunoglobulins, Intravenous; Infliximab; Mucocutaneous Lymph Node Syndrome; Yersinia enterocolitica | 2021 |
IgG levels in Kawasaki disease and its association with clinical outcomes.
Topics: Aspirin; Child; Child, Preschool; Cyclosporine; Female; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Infant; Logistic Models; Male; Mucocutaneous Lymph Node Syndrome; Platelet Aggregation Inhibitors; Prognosis; Retreatment; Retrospective Studies; Treatment Outcome | 2019 |
Kawasaki disease-related arthritis with synovial involvement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Aspirin; Child, Preschool; Cyclosporine; Diagnosis, Differential; Female; Humans; Immunoglobulins, Intravenous; Interleukin-18; Magnetic Resonance Imaging; Mucocutaneous Lymph Node Syndrome; Synovial Membrane | 2019 |
Improving coronary artery outcomes for children with Kawasaki disease.
Topics: Child; Coronary Artery Disease; Cyclosporine; Humans; Immunoglobulins, Intravenous; Mucocutaneous Lymph Node Syndrome | 2019 |
Cyclosporine and coronary outcomes in Kawasaki disease.
Topics: Coronary Artery Disease; Coronary Vessels; Cyclosporine; Humans; Immunoglobulins, Intravenous; Mucocutaneous Lymph Node Syndrome | 2019 |
[Cyclosporin A treatment for refractory Kawasaki disease].
Topics: Cyclosporine; Cytokines; Humans; Immunoglobulins, Intravenous; Mucocutaneous Lymph Node Syndrome; Signal Transduction | 2014 |
Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Male; Mucocutaneous Lymph Node Syndrome | 2016 |
Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.
Topics: Child, Preschool; Cyclosporine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infant; Male; Mucocutaneous Lymph Node Syndrome; Pilot Projects | 2011 |
Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Topics: Child; Child, Preschool; Clinical Protocols; Cyclosporine; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Infant; Male; Mucocutaneous Lymph Node Syndrome; T-Lymphocytes; Tacrolimus; Treatment Failure | 2012 |
Large vessel arteritis associated with human herpesvirus 6 infections.
Topics: Angiography; Aorta; Arteritis; Cyclophosphamide; Cyclosporine; Diagnosis, Differential; DNA, Viral; Fluorescent Antibody Technique, Indirect; Herpesvirus 6, Human; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Mucocutaneous Lymph Node Syndrome; Polymerase Chain Reaction; Roseolovirus Infections; Virus Replication | 2002 |
Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Methylprednisolone; Mucocutaneous Lymph Node Syndrome; Recurrence | 2001 |